Effects of androstenedione on in utero development in rats
Introduction
Anabolic steroids are commonly utilized to treat people who have a hormone deficiency or who have muscle wasting due to cancer or HIV. They have also been utilized as performance enhancing drugs to increase muscle strength and size for competitive sports. Most anabolic steroids are available only by prescription and their availability is tightly controlled (Anabolic Steroid Control Act, 1990). However, the use of steroid supplements to enhance athletic performance has become popular. Steroid supplements are utilized not only because many believe that these supplements can be converted into testosterone or a similar compound in the body, but because, as dietary supplements, they are easily accessible and can be purchased through various commercial sources. One steroid supplement, androstenedione, has become popular because several well known athletes have admitted using it to enhance their athletic performance. Androstenedione is a naturally occurring steroid hormone produced either by the adrenal glands or gonads and can be converted to either testosterone by the enzyme 17 beta-hydroxysteroid dehydrogenase or to an estrogen (i.e., estradiol or estrone) by the aromatase enzyme. It is sold in health food stores in the form of percutaneous gels, transdermal patches and chewing gums.
The use of steroid/steroid precursors/steroid supplements to elevate testosterone and possible estrogen levels may lead to adverse consequences such as liver and kidney damage in both males and females; acne, premature baldness, gynecomastia, enlarged prostate and reduced sperm production in males; and a disrupted menstrual cycle, deepened voice, increased facial hair growth (hirsutism) and clitomegaly in females (McEvoy, 1995). Use by children can lead to early puberty and premature cessation of bone growth.
Steroid use by high school and college students has been documented (Buckley et al., 1988, Terney and McLain, 1990, NIDA, 2000), and it has recently been reported that the use of steroids now extends to children and young adolescents even though this population is aware of the potential adverse effects of steroid use (Faigenbaum et al., 1998). Studies of self-reported use show that a significant number of adolescents have experimented with anabolic-androgenic steroid use (Yesalis et al., 1993, Yesalis, 1997) and it has been reported that steroid abuse by junior high and high school girls doubled between 1991 and 1998 (Yesalis, 1998). It has been suggested that this increase in steroid abuse may reflect increased athletic opportunities for young women and an increased interest in self-image among teen-age girls. It has also been suggested that a lean muscular “hard body” image popular among actresses and models may be prompting young girls to imitate these so-called ideal body images. Many teen age girls now desire to look healthier and somewhat more muscular, and this has led some girls toward an unhealthy compulsion to be ever fitter with larger muscles (Yesalis, 1998). Unfortunately, there is very little prospective data available regarding the safety of most steroid supplements. The following study was conducted in order to characterize the effects of androstenedione, a model steroid supplement, on female reproductive function using rats as an experimental model. The objectives of this study were: (1) to characterize the effect of androstenedione exposure on estrous cyclicity and mating behavior in young animals, and (2) to characterize the effect of gestational exposure to androstenedione on fetal development.
Section snippets
Test compound/dosing solutions
The test compound, androstenedione, was obtained from Steraloids, Newport, RI. The androstenedione utilized in this study was determined to be >99% pure by both thin layer chromatography and mass spectroscopy. The compound was delivered to the experimental animals in corn oil. Dosing solutions were stable for >35 days as determined by HPLC analysis. All solutions of androstenedione were prepared and used according to the results of the stability tests. The dosing solutions were not utilized
Experimental design
The animals were isolated and acclimated to their environment for approximately one week.
During the acclimation period the rats were singly housed in polycarbonate tubs and received pelleted Purina Chow 5002 and water (Hydro Systems water) ad libitum. After the acclimation period, female rats were given unique ear tags and assigned to either an androstenedione treatment group or a control group by weight according to a stratified random method at the initiation of the study. Female rats
Radioimmunoassay
Estradiol, estrone, testosterone and androstenedione were measured in duplicate samples of serum using the following kits: (1) Estradiol- Immu Chem Double Antibody 17 beta-estradiol RIA Kit (ICN Pharmaceuticals); (2) estrone- Estrone RIA Kit (ICN Pharmaceutical, Inc.),; (3) Testosterone- T-DPC Coat-a-Count Total testosterone kit and (4) Androstenedione- 125- I Androstenedione RIA Kit (ICN Biomedicals, Inc.). The assay sensitivity was 10 pg/tube for estradiol; 15 pg/ml for estrone; 0.2 ng/ml for
Statistical Analysis
For the parameters feed and fluid consumption, number of corpora lutea, implants, alive, males and females alive and estrous cyclicity data an Analysis of Variance (ANOVA) followed by a protected least significance difference (LSD) test (one-tail, if ANOVA p<0.05) was used to compare the control with each of the treated groups. For the parameters implant efficiency and percent early, late, and total (early+late) resorptions, the data were transformed using a Freeman-Tukey Arc-Sine
Results
Dose-related increases in serum androstenedione levels were observed in all treated groups, and statistically significant increases were seen in the 5.0, 10.0 and 30.0 mg/kg dose groups. Dose related statistically significant increases in serum estrone levels were observed in all treated groups in comparison to the controls. A dose-related increase in serum estradiol levels was observed in all treated groups, and the increase was significant in the 10.0 and 30.0 mg/kg dose groups. Serum
Discussion
The objectives of this study were to examine the possibility that androstenedione exposure adversely affected estrous cyclicity, mating behavior and fetal development. In order to test these hypotheses we designed an experiment in which young female rats were exposed, by gavage, to androstenedione in corn oil at one of four different dose levels (1.0, 5.0, 10.0, 30.0 mg/kg body weight) for two weeks prior to mating, during the mating period and throughout gestation. On gestation day 20, females
Acknowledgements
Special thanks are due to James I. Rorie for his very capable and experienced technical assistance during the study. Many thanks are due to the personnel from Row Sciences, Inc. who provided feed and animals husbandry services during the study. This research was funded by the Food and Drug Administrations Office of Women's Health.
References (26)
- et al.
The effects of 17-alpha-methyltestosterone, methandrosterolone and nandrolone decanoate on the rat estrous cycle
Physol. Behav.
(1997) Effects of prolonged exposure to anabolic steroids on the behavior of male and female mice
Pharmacol. Biochem. Behav.
(1996)- et al.
Effect of anabolic steroids on behavior and physiological characteristics of female mice
Physol. Behav.
(1996) - et al.
Androstenedione stimulates progesterone production in corpora lutea of pregnant ratsan effect not mediated by oestrogen
J. Steroid Biochem. Mol. Biol.
(1994) - et al.
Stanozolol, oxymetholone, and testosterone cypionate effects on the rat estrous cycle
Physiol. Behav.
(1998) - Anabolic Steroid Control Act of 1990, Title 21, Chapter 13 of the United States...
- et al.
Estimated prevalence of anabolic steroid use among male high school seniors
JAMA
(1988) - et al.
Chronic administration of anabolic steroids disrupts pubertal onset amd estrous cyclicity in rats
Biol. Reprod.
(2003) - Cooper R.L., Goldman J.M. 1999. Vaginal cytology. In AnEvaluation and Interpretation of Reproductive Endpoints for...
- et al.
Anabolic Steroid Use by Male and Female Middle School Students
Pediatrics
(1998)
Effect of androstenedione on the estrous cycle of the rat
J. Reprod. Fert.
Androstenedione interferes in luteal regression by inhibiting apoptosis and stimulating progesterone production
Biol. Reprod.
Cited by (14)
Pharmacological blockade of the aromatase enzyme, but not the androgen receptor, reverses androstenedione-induced cognitive impairments in young surgically menopausal rats
2015, SteroidsCitation Excerpt :Vehicle-treated animals received 0.5 ml of polyethylene glycol (PEG) (Sigma–Aldrich, St. Louis, MO, USA) only. All rats receiving androstenedione (Steraloids, Newport, RI, USA) were given 2 mg daily dissolved in PEG; this dose of androstenedione was based on previous literature [32,44,12] and has been shown to produce working memory impairments in middle-aged Ovx rats [12]. Animals in the Androstenedione + Anastrozole group received 0.025 mg/day anastrozole (Tocris, Minneapolis, MN, USA) co-administered with 2 mg androstenedione treatment, in order to block activity of the aromatase enzyme, preventing the conversion of androstenedione to estrone.
Maternal exposure to androstenedione does not induce developmental toxicity in the rat
2005, Food and Chemical ToxicologyEffects of oral androstenedione on steroid metabolism in liver of pregnant and non-pregnant female rats
2005, Food and Chemical ToxicologyHepatotoxicity of androstenedione in pregnant rats
2005, Food and Chemical ToxicologyCitation Excerpt :There is a potential for young women of child bearing age to inadvertently become pregnant while taking these steroids. Therefore, the present study was undertaken to determine the effects of oral exposure to androstenedione on reproduction in young female rats (Sprando et al., 2004). Because pregnancy is known to alter rat hepatic drug metabolism (Borlakoglu et al., 1993), livers from these animals were utilized to determine the hepatotoxic potential of this steroid in pregnant rats.
Effects of androgens and estrogens on sirtuin 1 gene expression in human aortic endothelial cells
2020, Saudi Medical Journal